A localized paediatric intracranial tumour is a representative indication where proton therapy can reduce unnecessary absorbed dose to the developing brain and other normal tissue. The finite particle range can reduce exit and integral dose compared with many photon radiotherapy plans, which may reduce late effects and secondary cancer risk over a long expected survival. It remains necessary to maintain target coverage, account for changing anatomy and keep uncertain distal-edge relative biological effectiveness away from sensitive structures. Travel, cost and daily positioning are practical disadvantages. The relevant comparison is a robust individual treatment plan and clinical endpoint, rather than the label “proton” alone.[ref]
ACR-ARS practice parameter for proton beam therapy. Paediatric treatment considerations and sparing of developing normal tissues
Ancestors (13)
- i
- b
- 3
- S10
- 2019
- Past exam of the short options paper shared by Parts A and B of the physics course of the University of Oxford
- Short options paper shared by Parts A and B of the physics course of the University of Oxford
- Physics course of the University of Oxford
- Undergraduate course of the University of Oxford
- Course of the University of Oxford
- University of Oxford
- List of universities
- Home
Discussion (0)
New discussionThere are no discussions about this article yet.
Articles by others on the same topic (0)
There are currently no matching articles.